Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Marius M HoeperDavid B BadeschH Ardeschir GhofraniJ Simon R GibbsMardi Gomberg-MaitlandVallerie V McLaughlinIoana R PrestonRogério de SouzaAaron B WaxmanEkkehard GrünigGrzegorz KopećGisela MeyerKaren M OlssonStephan RosenkranzYayun XuBarry MillerMarcie FowlerJohn ButlerJoerg KoglinJanethe de Oliveira PenaMarc Humbertnull nullPublished in: The New England journal of medicine (2023)
In patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. (Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988.).